NCT01813019 - Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Patient Diagnosed With OCD and Resistant to SSRI TreatmentFailed SSRI Over 12 Weeks at Appropriate Doses

Interventions

DRUG

AFQ056

mGluR5 antagonist

DRUG

Placebo

Matched placebo

Trial Locations (15)

1431

Novartis Investigative Site, Sofia

1632

Novartis Investigative Site, Sofia

3010

Novartis Investigative Site, Bern

4400

Novartis Investigative Site, Pazardzhik

8000

Novartis Investigative Site, Burgas

9020

Novartis Investigative Site, Varna

10117

Novartis Investigative Site, Berlin

11229

Novartis Investigative Site, Brooklyn

79106

Novartis Investigative Site, Freiburg im Breisgau

80336

Novartis Investigative Site, München

89081

Novartis Investigative Site, Ulm

90419

Novartis Investigative Site, Nuremberg

92103

Novartis Investigative Site, San Diego

02472

Novartis Investigative Site, Watertown

386 29

Novartis Investigative Site, Strakonice